Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5871698 | 0.81 | ALDH1A1 (0.41) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL1934716 | 0.75 | ALDH1A1 (0.50) | ALDH1A1TSHRKCNA5 | |
| SCHEMBL2102326 | 0.74 | HTR1A (0.43) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL27540862 | 0.72 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL3119794 | 0.72 | ALDH1A1 (0.46) | ALDH1A1TSHRKCNA5POLB | |
| SCHEMBL27645842 | 0.71 | TDP1 (0.31) | — | |
| SCHEMBL9084422 | 0.71 | CASP1 (0.36) | ALDH1A1 | |
| SCHEMBL7448545 | 0.70 | SMN1; SMN2 (0.53) | ALDH1A1SMN1; SMN2TSHRPOLB | |
| SCHEMBL22728352 | 0.70 | ALDH1A1 (0.45) | ALDH1A1TSHRKCNA5 | |
| SCHEMBL9082309 | 0.70 | LTA4H (0.38) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8952014-B2 | Pyrimidine derivatives which are CGRP—antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-02-10 | — | — | US | disclosed |
| US-8829006-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-09-09 | — | — | US | disclosed |
| US-20120088755-A1 | Novel Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-04-12 | — | — | US | disclosed |
| US-20110195954-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-11 | — | — | US | disclosed |
| EP-2332909-A1 | Hydroxybenzamide derivatives and their use as inhibitors of HSP90 | Astex Therapeutics Limited (GB) | 2011-06-15 | — | — | EP | disclosed |
| CN-1533390-A | Pharmaceutical composition comprising triazaspiro [5.5] undecane derivative as active ingredient | СҰҩƷ��ҵ��ʽ���� | 2004-09-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088755-A1 | Novel Compounds | SLC26A4, F12, SLCO1B3 | ALDH1A1 887/4885SMN1; SMN2 4269/4885TSHR 1696/4885 |
| US-20110195954-A1 | NOVEL COMPOUNDS | CALCRL, CALCR, CALCA | ALDH1A1 1405/4885SMN1; SMN2 4305/4885TSHR 562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.